120 related articles for article (PubMed ID: 22339435)
21. Is hydroxyurea leukemogenic in essential thrombocythemia?
Tefferi A
Blood; 1998 Aug; 92(4):1459-60; author reply 1460-1. PubMed ID: 9694740
[No Abstract] [Full Text] [Related]
22. Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients.
Macedo LC; de Cesare Quintero F; Pagliari-E-Silva S; Pagnano KB; Rodrigues C; de Alencar JB; Sell AM; Visentainer JE
Blood Cells Mol Dis; 2016 Mar; 57():54-7. PubMed ID: 26852656
[TBL] [Abstract][Full Text] [Related]
23. Philadelphia chromosome positive myelodysplastic syndrome and acute myelogenous leukemia.
Advani AS
Leuk Res; 2004 Jun; 28(6):545-6. PubMed ID: 15120928
[No Abstract] [Full Text] [Related]
24. BRAF mutations in hairy-cell leukemia.
Pardanani A; Tefferi A
N Engl J Med; 2011 Sep; 365(10):961; author reply 961-2. PubMed ID: 21899462
[No Abstract] [Full Text] [Related]
25. [Essential thrombocythemia, chronic myeloid leukemia or polycythemia vera].
GOUDSMIT R
Ned Tijdschr Geneeskd; 1956 Apr; 100(17):1236-9. PubMed ID: 13322104
[No Abstract] [Full Text] [Related]
26. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.
Shide K; Shimoda HK; Kumano T; Karube K; Kameda T; Takenaka K; Oku S; Abe H; Katayose KS; Kubuki Y; Kusumoto K; Hasuike S; Tahara Y; Nagata K; Matsuda T; Ohshima K; Harada M; Shimoda K
Leukemia; 2008 Jan; 22(1):87-95. PubMed ID: 18033315
[TBL] [Abstract][Full Text] [Related]
27. The BRAF-V600E mutation in hematological malignancies: a new player in hairy cell leukemia and Langerhans cell histiocytosis.
Tadmor T; Tiacci E; Falini B; Polliack A
Leuk Lymphoma; 2012 Dec; 53(12):2339-40. PubMed ID: 22738431
[No Abstract] [Full Text] [Related]
28. FOXP1 Expression in Normal and Neoplastic Erythroid and Myeloid Cells.
Lovrić E; Pavlov KH; Korać P; Dominis M
Coll Antropol; 2015 Sep; 39(3):755-9. PubMed ID: 26898077
[TBL] [Abstract][Full Text] [Related]
29. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
30. Cytogenetics of chronic myeloproliferative disorders and related myelodysplastic syndromes.
Adeyinka A; Dewald GW
Hematol Oncol Clin North Am; 2003 Oct; 17(5):1129-49. PubMed ID: 14560778
[TBL] [Abstract][Full Text] [Related]
31. Myeloproliferative Neoplasms.
Spivak JL
N Engl J Med; 2017 Jun; 376(22):2168-2181. PubMed ID: 28564565
[No Abstract] [Full Text] [Related]
32. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
33. ANKRD26-related thrombocytopenia and myeloid malignancies.
Noris P; Favier R; Alessi MC; Geddis AE; Kunishima S; Heller PG; Giordano P; Niederhoffer KY; Bussel JB; Podda GM; Vianelli N; Kersseboom R; Pecci A; Gnan C; Marconi C; Auvrignon A; Cohen W; Yu JC; Iguchi A; Miller Imahiyerobo A; Boehlen F; Ghalloussi D; De Rocco D; Magini P; Civaschi E; Biino G; Seri M; Savoia A; Balduini CL
Blood; 2013 Sep; 122(11):1987-9. PubMed ID: 24030261
[No Abstract] [Full Text] [Related]
34. Quantification of JAK2V617F mutation by next-generation sequencing technology.
Abdelhamid E; Figeac M; Renneville A; Quief S; Villenet C; Boyer T; Nibourel O; Coiteux V; Cassinat B; Lippert E; Helevaut N; Soua Z; Preudhomme C
Am J Hematol; 2013 Jun; 88(6):536-7. PubMed ID: 23553621
[No Abstract] [Full Text] [Related]
35. [Management strategy for BCR-ABL negative myeloproliferative neoplasms].
Gotoh A; Komatsu N
Rinsho Ketsueki; 2014 Jan; 55(1):56-65. PubMed ID: 24492037
[No Abstract] [Full Text] [Related]
36. PU.1 expression is restored upon treatment of chronic myeloid leukemia patients.
Albajar M; Gutierrez P; Richard C; Rosa-Garrido M; Gómez-Casares MT; Steegmann JL; León J; Delgado MD
Cancer Lett; 2008 Nov; 270(2):328-36. PubMed ID: 18635311
[TBL] [Abstract][Full Text] [Related]
37. Inheritance of the chronic myeloproliferative neoplasms. A systematic review.
Ranjan A; Penninga E; Jelsig AM; Hasselbalch HC; Bjerrum OW
Clin Genet; 2013 Feb; 83(2):99-107. PubMed ID: 23094849
[TBL] [Abstract][Full Text] [Related]
38. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia.
Christiansen DH; Andersen MK; Desta F; Pedersen-Bjergaard J
Leukemia; 2005 Dec; 19(12):2232-40. PubMed ID: 16281072
[TBL] [Abstract][Full Text] [Related]
39. A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis.
Bellosillo B; Martínez-Avilés L; Gimeno E; Florensa L; Longarón R; Navarro G; Salar A; Espinet B; Solé F; Serrano S; Besses C
Leukemia; 2007 Jun; 21(6):1331-2. PubMed ID: 17361221
[No Abstract] [Full Text] [Related]
40. MYELOPROLIFERATIVE SYNDROME; EVALUATION OF MYELOSCLEROSIS AND CHRONIC MYELOGENOUS LEUKEMIA TO POLYCYTHEMIA VERA.
LOPAS H; JOSEPHSON AM
Arch Intern Med; 1964 Dec; 114():754-9. PubMed ID: 14211587
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
